抗丙型肝炎病毒藥索非布韋的臨床研究進(jìn)展
發(fā)布時(shí)間：2019-06-05 19:02
【摘要】：目的:綜述抗丙型肝炎病毒(HCV)藥索非布韋的臨床研究進(jìn)展。方法:以"Sofosbuvir""索非布韋""索氟布韋""丙型肝炎"和"NS5B聚合酶抑制劑"等為關(guān)鍵詞,組合檢索2010年1月至2015年2月Pub Med、萬方、維普、中國知網(wǎng)等數(shù)據(jù)庫,對(duì)索非布韋的臨床藥理(作用機(jī)制、藥動(dòng)學(xué)、藥物相互作用、耐藥性)、適用特殊人群、臨床試驗(yàn)及安全性評(píng)價(jià)等內(nèi)容進(jìn)行綜述。結(jié)果:共檢索到相關(guān)文獻(xiàn)76條,其中有效文獻(xiàn)20條。作用機(jī)制方面,索非布韋通過與HCV的RNA核苷酸競(jìng)爭(zhēng)HCV特異性NS5B聚合酶活化位點(diǎn)而發(fā)揮抗病毒作用,給藥劑量為400 mg/d時(shí)對(duì)病毒的抑制作用最佳。臨床應(yīng)用方面,索非布韋適用于HCV初治患者和既往干擾素治療失敗的患者,不同HCV基因型感染可采用不同的給藥方案;索非布韋對(duì)HCV感染合并肝硬化、肝臟移植和人類免疫缺陷病毒感染患者也有效,且給藥時(shí)無需調(diào)整劑量。此外,索非布韋的耐藥性較好、藥物相互作用少、不良事件發(fā)生率較低。結(jié)論:索非布韋用于慢性HCV感染治療,具有病毒學(xué)應(yīng)答率高、適用人群廣、不良反應(yīng)發(fā)生率低、給藥方式簡單等特點(diǎn),相信在未來會(huì)擁有良好的應(yīng)用前景。
[Abstract]:Objective: to review the clinical research progress of sofebuvir, an anti-hepatitis C virus (HCV) drug. Methods: using "Sofosbuvir", "sofebwe", "sofebuvir", "hepatitis C" and "NS5B polymerase inhibitor" as keywords, the databases of Pub Med, Wanfang, Weipu and China knowledge Network from January 2010 to February 2015 were searched. The clinical pharmacology (mechanism of action, pharmacokinetics, drug interaction, drug resistance), application of special population, clinical trial and safety evaluation of sofebuvir were reviewed. Results: a total of 76 related literatures were searched, of which 20 were effective. In terms of mechanism, Sofebwe played an antiviral role by competing with RNA nucleotides of HCV for HCV specific NS5B polymerase activation sites, and the inhibitory effect on the virus was the best at the dose of 400 mg/d. In clinical application, sofebuvir is suitable for newly treated patients with HCV and patients with failed interferon therapy. Different HCV genotypic infections can be treated with different drug administration schemes. Sofebuvir is also effective in patients with HCV infection complicated with liver cirrhosis, liver transplantation and human immunodeficiency virus infection, and there is no need to adjust the dose during administration. In addition, the drug resistance of sofebuvir was good, the drug interaction was less, and the incidence of adverse events was low. Conclusion: sofebuvir is used in the treatment of chronic HCV infection with the characteristics of high virological response rate, wide application population, low incidence of adverse reactions and simple administration. It is believed that sofebuvir will have a good application prospect in the future.
【作者單位】： 臺(tái)州恩澤醫(yī)療中心(集團(tuán))恩澤醫(yī)院藥劑科;杭州市余杭區(qū)第二人民醫(yī)院藥劑科;
【分類號(hào)】：R969.3
本文編號(hào)：2493754
[Abstract]:Objective: to review the clinical research progress of sofebuvir, an anti-hepatitis C virus (HCV) drug. Methods: using "Sofosbuvir", "sofebwe", "sofebuvir", "hepatitis C" and "NS5B polymerase inhibitor" as keywords, the databases of Pub Med, Wanfang, Weipu and China knowledge Network from January 2010 to February 2015 were searched. The clinical pharmacology (mechanism of action, pharmacokinetics, drug interaction, drug resistance), application of special population, clinical trial and safety evaluation of sofebuvir were reviewed. Results: a total of 76 related literatures were searched, of which 20 were effective. In terms of mechanism, Sofebwe played an antiviral role by competing with RNA nucleotides of HCV for HCV specific NS5B polymerase activation sites, and the inhibitory effect on the virus was the best at the dose of 400 mg/d. In clinical application, sofebuvir is suitable for newly treated patients with HCV and patients with failed interferon therapy. Different HCV genotypic infections can be treated with different drug administration schemes. Sofebuvir is also effective in patients with HCV infection complicated with liver cirrhosis, liver transplantation and human immunodeficiency virus infection, and there is no need to adjust the dose during administration. In addition, the drug resistance of sofebuvir was good, the drug interaction was less, and the incidence of adverse events was low. Conclusion: sofebuvir is used in the treatment of chronic HCV infection with the characteristics of high virological response rate, wide application population, low incidence of adverse reactions and simple administration. It is believed that sofebuvir will have a good application prospect in the future.
【作者單位】： 臺(tái)州恩澤醫(yī)療中心(集團(tuán))恩澤醫(yī)院藥劑科;杭州市余杭區(qū)第二人民醫(yī)院藥劑科;
【分類號(hào)】：R969.3
【參考文獻(xiàn)】
相關(guān)期刊論文 前1條
1 劉正和;;全球首個(gè)抗HCV全口服新藥索非布韋[J];山東化工;2014年04期
【相似文獻(xiàn)】
相關(guān)期刊論文 前2條
1 邢麗妍;胡春;;索非布韋[J];中國藥物化學(xué)雜志;2014年04期
2 ;[J];;年期
，本文編號(hào)：2493754
本文鏈接：http://sikaile.net/yixuelunwen/yiyaoxuelunwen/2493754.html
最近更新
教材專著
